Follow
Lawrence Leiter
Lawrence Leiter
Verified email at smh.ca
Title
Cited by
Cited by
Year
Heart disease and stroke statistics—2016 update: a report from the American Heart Association
D Mozaffarian, EJ Benjamin, AS Go, DK Arnett, MJ Blaha, M Cushman, ...
circulation 133 (4), e38-e360, 2016
74134*2016
Dapagliflozin and cardiovascular outcomes in type 2 diabetes
SD Wiviott, I Raz, MP Bonaca, O Mosenzon, ET Kato, A Cahn, ...
New England Journal of Medicine 380 (4), 347-357, 2019
56292019
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
SP Marso, SC Bain, A Consoli, FG Eliaschewitz, E Jódar, LA Leiter, ...
New England Journal of Medicine 375 (19), 1834-1844, 2016
51172016
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
BM Scirica, DL Bhatt, E Braunwald, PG Steg, J Davidson, B Hirshberg, ...
New England Journal of Medicine 369 (14), 1317-1326, 2013
41522013
Effects of combination lipid therapy in type 2 diabetes mellitus
ACCORD Study Group
New England Journal of Medicine 362 (17), 1563-1574, 2010
34182010
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome …
TA Zelniker, SD Wiviott, I Raz, K Im, EL Goodrich, MP Bonaca, ...
The Lancet 393 (10166), 31-39, 2019
25572019
Effects of dalcetrapib in patients with a recent acute coronary syndrome
GG Schwartz, AG Olsson, M Abt, CM Ballantyne, PJ Barter, J Brumm, ...
New England Journal of Medicine 367 (22), 2089-2099, 2012
22482012
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ...
The Lancet 394 (10193), 121-130, 2019
21832019
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
HH Parving, BM Brenner, JJV McMurray, D De Zeeuw, SM Haffner, ...
New England Journal of Medicine 367 (23), 2204-2213, 2012
16142012
Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society consensus panel statement on assessment, aetiology and management
ES Stroes, PD Thompson, A Corsini, GD Vladutiu, FJ Raal, KK Ray, ...
European heart journal 36 (17), 1012-1022, 2015
14842015
Sotagliflozin in patients with diabetes and recent worsening heart failure
DL Bhatt, M Szarek, PG Steg, CP Cannon, LA Leiter, DK McGuire, ...
New England journal of medicine 384 (2), 117-128, 2021
13762021
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
AF Hernandez, JB Green, S Janmohamed, RB D'Agostino, CB Granger, ...
The Lancet 392 (10157), 1519-1529, 2018
13162018
2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult
TJ Anderson, J Grégoire, RA Hegele, P Couture, GBJ Mancini, ...
Canadian Journal of Cardiology 29 (2), 151-167, 2013
10842013
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult–2009 recommendations
J Genest, R McPherson, J Frohlich, T Anderson, N Campbell, ...
Canadian Journal of Cardiology 25 (10), 567-579, 2009
10692009
2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult
TJ Anderson, J Grégoire, GJ Pearson, AR Barry, P Couture, M Dawes, ...
Canadian Journal of Cardiology 32 (11), 1263-1282, 2016
10312016
Cholesterol lowering in intermediate-risk persons without cardiovascular disease
S Yusuf, J Bosch, G Dagenais, J Zhu, D Xavier, L Liu, P Pais, ...
New England Journal of Medicine 374 (21), 2021-2031, 2016
9942016
Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol
KK Ray, RS Wright, D Kallend, W Koenig, LA Leiter, FJ Raal, JA Bisch, ...
New England journal of medicine 382 (16), 1507-1519, 2020
9812020
Effect of valsartan on the incidence of diabetes and cardiovascular events
NAVIGATOR Study Group
New England Journal of Medicine 362 (16), 1477-1490, 2010
9302010
Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol
KK Ray, U Landmesser, LA Leiter, D Kallend, R Dufour, M Karakas, T Hall, ...
New England Journal of Medicine 376 (15), 1430-1440, 2017
9182017
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised …
WT Cefalu, LA Leiter, KH Yoon, P Arias, L Niskanen, J Xie, DA Balis, ...
The Lancet 382 (9896), 941-950, 2013
9012013
The system can't perform the operation now. Try again later.
Articles 1–20